Background and aim: The RPS14 gene, located on chromosome 5 and involved in the ribosomal protein synthesis, has been reported as a causal factor in the 5q- syndrome, where its up-regulation during treatment with lenalidomide has been associated with best responses. RPS14 expression in non-5q-MDS was reported in 53%-71% of cases. Interestingly, in low and intermediate-1 IPSS subgroups, patients with lower RPS14 expression had longer OS. Thus, the aim of this study was to assess the RPS14 expression in a larger series of non-5q- MDS patients. Patients and methods: A total of 112 patients, 45% females and 55% males, with a median age of 71-year (range 19-89), were enrolled in 5 different Italian institutions from March 2010 to October 2014. Nine patients were affected by CMMoL; the prognosis of the remaining 103 cases was determined according to the IPSS in low (36%), intermediate-1 (31%), intermediate-2 (21%), and high risk (12%). About 40% of cases were affected by RCMD, 24% by RAEB-2,and 13% by RA. Twelve bone marrow samples from healthy donors have been used as normal references. Results: In healthy donors, the mean RPS14 expression was 0.94±0.26; in the whole MDS series, it was 0.57±0.42. In comparison with healthy controls, the 52% of MDS cases showed lower RPS14 expression levels: 79% in the RA, 56% in the RAEB1, 44% in the RAEB-2, and 41% in the RCMD subgroups. When patients were stratified according to the IPSS, in the half of the low, intermediate-1 and intermediate-2 cases RPS14 was under-expressed, opposite to one third of the high risk and 13% of the CMMoL patients only. No relationships with age or sex were observed. To evaluate if the haploinsufficiency would be responsible of the low expression of RPS14 gene, we performed the copy number assay on 32 MDS, 15 healthy donors, and 3 patients with 5qsyndrome: in 91% of cases the copy number assay excluded the haploinsufficiency. Conclusions: Our study showed in a large series of patients that a lower RPS14 expression interests the half of the non-5q- cases, especially those affected by RA and at low and intermediate IPSS risk. Other authors previously reported that low expression of RPS14 was not due to promoter hypermethylation. Here we demonstrated that also the haploinsufficience is not the cause of the RPS14 low expression. Moreover, our findings suggest a possible role for lenalidomide in non-5q- MDS, especially in low risk patients.

LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES

GRASSI, SUSANNA;CIABATTI, ELENA;ROUSSEAU, MARTINA;GUERRINI, FRANCESCA;PETRINI, IACOPO;PETRINI, MARIO;GALIMBERTI, SARA
2015-01-01

Abstract

Background and aim: The RPS14 gene, located on chromosome 5 and involved in the ribosomal protein synthesis, has been reported as a causal factor in the 5q- syndrome, where its up-regulation during treatment with lenalidomide has been associated with best responses. RPS14 expression in non-5q-MDS was reported in 53%-71% of cases. Interestingly, in low and intermediate-1 IPSS subgroups, patients with lower RPS14 expression had longer OS. Thus, the aim of this study was to assess the RPS14 expression in a larger series of non-5q- MDS patients. Patients and methods: A total of 112 patients, 45% females and 55% males, with a median age of 71-year (range 19-89), were enrolled in 5 different Italian institutions from March 2010 to October 2014. Nine patients were affected by CMMoL; the prognosis of the remaining 103 cases was determined according to the IPSS in low (36%), intermediate-1 (31%), intermediate-2 (21%), and high risk (12%). About 40% of cases were affected by RCMD, 24% by RAEB-2,and 13% by RA. Twelve bone marrow samples from healthy donors have been used as normal references. Results: In healthy donors, the mean RPS14 expression was 0.94±0.26; in the whole MDS series, it was 0.57±0.42. In comparison with healthy controls, the 52% of MDS cases showed lower RPS14 expression levels: 79% in the RA, 56% in the RAEB1, 44% in the RAEB-2, and 41% in the RCMD subgroups. When patients were stratified according to the IPSS, in the half of the low, intermediate-1 and intermediate-2 cases RPS14 was under-expressed, opposite to one third of the high risk and 13% of the CMMoL patients only. No relationships with age or sex were observed. To evaluate if the haploinsufficiency would be responsible of the low expression of RPS14 gene, we performed the copy number assay on 32 MDS, 15 healthy donors, and 3 patients with 5qsyndrome: in 91% of cases the copy number assay excluded the haploinsufficiency. Conclusions: Our study showed in a large series of patients that a lower RPS14 expression interests the half of the non-5q- cases, especially those affected by RA and at low and intermediate IPSS risk. Other authors previously reported that low expression of RPS14 was not due to promoter hypermethylation. Here we demonstrated that also the haploinsufficience is not the cause of the RPS14 low expression. Moreover, our findings suggest a possible role for lenalidomide in non-5q- MDS, especially in low risk patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/819845
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact